(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 August 2018 (23.08.2018)

WIPO | PCT

(10) International Publication Number
WO 2018/151836 A8

(51) International Patent Classification:
A61K 31/55 (2006.01) *A61P 35/02* (2006.01)
A61K 39/395 (2006.01) *A61P 37/00* (2006.01)
A61K 35/17 (2015.01) *A61K 45/06* (2006.01)
A61P 37/02 (2006.01) *C12N 15/62* (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:
PCT/US2018/000050

(22) International Filing Date:
16 February 2018 (16.02.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/460,612 17 February 2017 (17.02.2017) US
62/582,270 06 November 2017 (06.11.2017) US

(71) Applicant: **FRED HUTCHINSON CANCER RESEARCH CENTER** [US/US]; 1100 Fairview Avenue North, Seattle, WA 98109 (US).

(72) Inventors: **RIDDELL, Stanley, R.**; 1763 268th Place SE, Sammamish, WA 98075 (US). **GREEN, Damian**; 2746 NE 88th Street, Seattle, WA 98115 (US). **HILL, Tyler**; 1315 N 88th Street, Seattle, WA 98103 (US).

(74) Agent: **PEPE, Jeffrey, C.** et al.; Seed Intellectual Property, Law Group LLP, 701 Fifth Avenue, Suite 5400, Seattle, WA 98104-7064 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,

(54) Title: COMBINATION THERAPIES FOR TREATMENT OF BCMA-RELATED CANCERS AND AUTOIMMUNE DISORDERS




FIG. 7B

(57) Abstract: The present disclosure relates to methods for using BCMA-specific binding molecules (such as a BCMA-specific chimeric antigen receptor or antibody) in combination with γ-secretase inhibitors, which can be done concurrently or sequentially, to treat or prevent a B-cell related proliferative disease, such as a cancer or autoimmune disease, or the like. A BCMA-specific binding molecule in combination with γ-secretase inhibitor can be used in, for example, adoptive immunotherapy.

WO 2018/151836 A8

[Continued on next page]

OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

(48) **Date of publication of this corrected version:**
15 November 2018 (15.11.2018)

(15) **Information about Correction:**
see Notice of 15 November 2018 (15.11.2018)